^
Association details:
| Biomarker: | EGFR L858R + RBM10 Y36* |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR mutant lung cancer
Excerpt:
In a second patient (Case #2) with co-occurring EGFR L858R and RBM10 Y36* mutations, again only SD was observed during erlotinib treatment (10 months)...Biopsy at the time of progression confirmed low RBM10 expression...Osimertinib was initiated in this case and there was immediate disease progression despite this treatment.
DOI:
10.1101/2020.10.26.356352
